Clinico-Genomic Database

Flatiron and Foundation Medicine’s real-world Clinico-Genomic Database (CGDB) integrates de-identified clinical data from electronic health records with comprehensive genomic profiling data.

Connect genomics with clinical outcomes

The CGDB allows researchers to accelerate precision oncology studies. Providing clinically meaningful data on 300+ genes sourced from 100k+ patient records, the CGDB enables both disease-specific and disease-agnostic analyses. Patient data from early through metastatic disease stages are included in the majority of datasets, with up to 3-month recency.  


Unlocking insights: Flatiron’s disease-specific and agnostic real-world data models

Disease-specific data models

The CGDB includes data on 20 disease types:

  • Acute myeloid leukemia
  • Advanced bladder cancer
  • Breast cancer
  • Chronic lymphocytic leukemia
  • Colorectal cancer
  • Diffuse large B-Cell lymphoma
  • Advanced endometrial cancer
  • Follicular lymphoma
  • Gastric/Esophageal/GEJ cancer
  • Head and neck cancer
  • Hepatocellular carcinoma
  • Mantle cell lymphoma
  • Melanoma
  • Multiple myeloma
  • Non-small cell lung cancer
  • Ovarian cancer
  • Pancreatic cancer
  • Metastatic prostate cancer
  • Renal cell carcinoma
  • Small cell lung cancer
Disease-agnostic data models

Our disease-agnostic datasets combine 20 disease-specific data models with a lighter-weight data model for all other histologies to enable robust pan-tumor analyses. 

Comprehensive genomic profiling

The CGDB contains robust genomic profiling data across solid and liquid biopsies utilizing circulating tumor DNA (ctDNA), and offers complex biomarker information such as tumor mutational burden (TMB), microsatellite instability (MSI) status, and PD-L1 results.

By the numbers

Patients linked in the CGDB
Genes in the CGDB
Publications enabled with 15+ biopharma partners

Originally stemming from a high-priority need for real-world data, we were able to foster a new collaboration with Flatiron and Foundation Medicine and utilize their large data source of rich clinical and genomic data, representing a substantial proportion of community oncology patients nationally.

Hil Hsu, PhD, MPH Senior Manager, Center for Observational Research

Source: ResearchX

Derive real-world endpoints using validated outcome variables


Real-world overall survival

Conduct robust survival analyses with our validated mortality variable, available with all CGDB subscriptions. 

See validation study


Real-world progression-free survival

Analyze real-world progression-related endpoints across observational RWE studies with our validated real-world progression (rwP) variable, available with certain CGDB subscriptions. 

See validation study


Real-world response endpoints

Analyze real-world response-related endpoints to support clinical development or regulatory decision making with our validated real-world response (rwR) variable, available with certain CGDB subscriptions. 

See validation study

Explore more integrated real-world evidence products

Flatiron’s customizable real-world data products integrate EHR-derived data with other data modalities.
Pattern C - Color Palette 5

Get in touch

Learn more about the Clinico-Genomic Database.